Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp WT (NQ: LEXXW ) 1.530 UNCHANGED Streaming Delayed Price Updated: 9:44 AM EDT, Jun 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 1.530 Bid (Size) 1.250 (100) Ask (Size) 1.500 (20) Prev. Close 1.530 Today's Range 1.530 - 1.530 52wk Range 0.0500 - 2.500 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study June 05, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study May 23, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Performance YTD +206.00% +206.00% 1 Month +39.09% +39.09% 3 Month +6.25% +6.25% 6 Month +240.08% +240.08% 1 Year +565.22% +565.22% More News Read More Lexaria Awards Contract For Third GLP-1 Human Pilot Study May 23, 2024 Via ACCESSWIRE Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy May 21, 2024 Via ACCESSWIRE Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study May 17, 2024 Via ACCESSWIRE Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study April 16, 2024 Via ACCESSWIRE Lexaria Awarded New Patents April 02, 2024 Via ACCESSWIRE Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study May 08, 2024 Via ACCESSWIRE Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs May 06, 2024 Via ACCESSWIRE Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance April 30, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH April 16, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO March 14, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Appoints Nelson Cabatuan as Chief Financial Officer March 14, 2024 Via ACCESSWIRE Lexaria Awards Contract For Next GLP-1 Human Pilot Study March 07, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study March 05, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 March 05, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study March 04, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property 7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study March 04, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial March 01, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Product Safety Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial March 01, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering February 20, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules February 16, 2024 Via ACCESSWIRE Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules February 15, 2024 Via ACCESSWIRE Lexaria's Submits Investigational New Drug Application January 30, 2024 Via ACCESSWIRE Lexaria Releases Annual Letter from the CEO January 24, 2024 Via ACCESSWIRE Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
